All In Biotech

Drug Trial Radar · NCT04986176

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

Last checked: Nov 20, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 602 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

602

Planned (sponsor's estimate)

Start

Apr 15, 2022

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Applied Biology, Inc.Industry
Sponsor type
Industry
Collaborators
Hinova Pharmaceuticals Inc.
First posted
Aug 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.

Conditions

  • COVID-19 Respiratory Infection

Interventions

  • HC-1119Drug

    oral

  • PlaceboDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality risk ratio assessed by the proportion of patient deaths in both study arms.Time frame: 28 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.